the aims of this article are to provide an overview of the current status of the arbutus biopharma corporation ( adv ) and to provide an overview of the current status of our efforts to improve the treatment of hepatitis b and its potential for a cure. we will also provide a discussion of the current state of our research and the current status of our research efforts.